Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

Please provide your email address to receive an email when new articles are posted on . Published results showed integration of fracture liaison and orthopedic services, as well as inpatient ...

Bisphosphonate therapy should continue as long as the patient is able to tolerate therapy or until evidence of a substantial decline in performance status. A serum creatinine measurement should be ...

The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

BRAMPTON, Ontario--(BUSINESS WIRE)--Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL ...

A new research paper, titled "In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers," was published on the cover of Aging Zoledronic acid ...

Bisphosphonates are the most commonly used therapeutic agents for Paget's disease. Although bisphosphonates are effective in normalizing the biochemical markers that cause the erratic bone turnover ...

Impact of palliative care on end-of-life management of cancer patients dying in the hospital. Assessment of the current implementation and barriers to uptake of the guidelines for the psychosocial ...

A single infusion of zoledronic acid reduces fracture risk for more than 1 year, new data suggest. Annual infusions of zoledronic acid reduce fracture risk in postmenopausal women with osteoporosis.

In general, IV bisphosphonates are very well tolerated, and patients rarely require dose modification. In the comparative phase 3 trial of zoledronic acid and pamidronate in patients with breast ...